Vorolanib

DB15247InvestigationalSmall molecule

Vorolanib is under investigation in clinical trial NCT03904719 (CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)).

Mechanism: Pharmacologically active on Vascular endothelial growth factor receptor
Curator reviewed
Formula / weight: C₂₃H₂₆FN₅O₃ · 439.491 g/mol (avg)
Code names: CM082 · EYP-1901 · X-82

Resolves to

Compound

Structure

InChIKeyKMIOJWCYOHBUJS-HAKPAVFJSA-NSMILESCN(C)C(=O)N1CC[C@@H](C1)NC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

29Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which companies are running trials of Vorolanib, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.